Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424..
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
   PubMed Web of Science ®Google Scholar
• Chen EY, Blanke CD, Haller DG, et al. A Phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer. Am J Clin Oncol. 2018;41(12):1193–1198.
   PubMed Web of Science ®Google Scholar
• Gasparini G, Gattuso D, Morabito A, et al. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. Oncologist. 2005;10(9):710–717.
   PubMed Web of Science ®Google Scholar
• Maroun J, Marginean H, Jonker D, et al. A Phase I study of irinotecan, capecitabine (Xeloda), and oxaliplatin in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2018;17(2):e257–e268.
   PubMed Web of Science ®Google Scholar
• Petrioli R, Francini E, Cherri S, et al. Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer. 2018;17(4):e663–e669.
   PubMed Web of Science ®Google Scholar
• Kusano M, Aoyama T, Okabayashi K, et al. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). J Cancer Res Ther. 2018;14(Supplement):S761–S766.
   PubMedGoogle Scholar
• Yuan L, Zhang S, Li H, et al. The influence of gut microbiota dysbiosis to the efficacy of 5-fluorouracil treatment on colorectal cancer. Biomed Pharmacother. 2018;108:184–193.
   PubMed Web of Science ®Google Scholar
• Noguerido A, Mulet-Margalef N, Matos I, et al. The safety of ramucirumab for the treatment of colorectal cancer. Expert Opin Drug Saf. 2018;17(9):945–951.
   PubMed Web of Science ®Google Scholar
• Ushida Y, Shinozaki E, Chin K, et al. Two cases of long-term survival of advanced colorectal cancer with synchronous lung metastases treated with mFOLFOX6/XELOX + bevacizumab. Case Rep Oncol. 2018;11(2):601–608.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Martinelli E, Cascinu S, et al. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label Phase IIIb CONSIGN Study. Oncologist. 2018.
   PubMed Web of Science ®Google Scholar
• Griffioen AW. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends Cardiovasc Med. 2007;17(5):171–176.
   PubMed Web of Science ®Google Scholar
• de Castro Junior G, Puglisi F, de Azambuja E, et al. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the ‘do ut des’ paradigm). Crit Rev Oncol Hematol. 2006;59(1):40–50.
   PubMed Web of Science ®Google Scholar
• Lin Z, Zhang Q, Luo W. Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions. Eur J Pharmacol. 2016;793:76–81.
   PubMed Web of Science ®Google Scholar
• Choudhari SK, Chaudhary M, Bagde S, et al. Nitric oxide and cancer: a review. World J Surg Oncol. 2013;11:118.
   PubMed Web of Science ®Google Scholar
• Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res. 2004;555(1–2):107–119.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick B, Mehibel M, Cowen RL, et al. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide. 2008;19(2):217–224.
   PubMed Web of Science ®Google Scholar
• Marcus DM. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2014;73(9):e56.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yan Y, Li Y. Tripterine alleviates LPS-induced inflammatory injury by up-regulation of miR-146a in HaCaT cells. Biomed Pharmacother. 2018;105:798–804.
   PubMed Web of Science ®Google Scholar
• Bufu T, Di X, Yilin Z, et al. Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. Anticancer Drugs. 2018;29(6):530–538.
   PubMed Web of Science ®Google Scholar
• Mi C, Shi H, Ma J, et al. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep. 2014;32(6):2527–2532.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang Z, Zhang S, et al. Inhibitory action of celastrol on hypoxia-mediated angiogenesis and metastasis via the HIF-1α pathway. Int J Mol Med. 2011;27(3):407–415.
   PubMed Web of Science ®Google Scholar
• Ma J, Han LZ, Liang H, et al. Celastrol inhibits the HIF-1α pathway by inhibition of mTOR/p70s6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. Oncol Rep. 2014;32(1):235–242.
   PubMed Web of Science ®Google Scholar
• Pang X, Yi Z, Zhang J, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010;70(5):1951–1959.
   PubMed Web of Science ®Google Scholar
• Ke C, Jin H, Cai J. AFM studied the effect of celastrol on β1 integrin-mediated HUVEC adhesion and migration. Scanning. 2013;35(5):316–326.
   PubMed Web of Science ®Google Scholar
• Gong F, Zhao F, Gan XD. Celastrol protects TGF-β1-induced endothelial-mesenchymal transition. J Huazhong Univ Sci Technol Med Sci. 2017;37(2):185–190.
   PubMedGoogle Scholar
• Li Z, Li J, Zhu L, et al. Celastrol nanomicelles attenuate cytokine secretion in macrophages and inhibit macrophage-induced corneal neovascularization in rats. Int J Nanomater. 2016;11:6135–6148.
   Google Scholar
• Ricciuti B, Foglietta J, Bianconi V, et al. Enzymes involved in tumor-driven angiogenesis: a valuable target for anticancer therapy. Semin Cancer Biol. 2017.
   PubMedGoogle Scholar
• Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000;6(12):4739–4744.
   PubMed Web of Science ®Google Scholar
• Ambs S, Bennett WP, Merriam WG, et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999;91(1):86–88.
   PubMedGoogle Scholar
• Ambs S, Merriam WG, Ogunfusika MO, et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med. 1998;4(12):1371–1376.
   PubMed Web of Science ®Google Scholar
• Ambs S, Bennett WP, Merriam WG, et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1998;78(2):233–239.
   PubMed Web of Science ®Google Scholar
• Falcon BL, Chintharlapalli S, Uhlik MT, et al. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacol Ther. 2016;164:204–225.
   PubMed Web of Science ®Google Scholar
• Jung HW, Chung YS, Kim YS, et al. Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-κB in LPS-stimulated BV-2 microglial cells. Exp Mol Med. 2007;39(6):715–721.
   PubMed Web of Science ®Google Scholar
• Boridy S, Soliman GM, Maysinger D. Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. Nanomedicine. 2012;7(8):1149–1165.
   PubMed Web of Science ®Google Scholar
• Mitselou A, Ioachim E, Skoufi U, et al. Predictive role of thymidine phosphorylase expression in patients with colorectal cancer and its association with angiogenesis-related proteins and extracellular matrix components. In Vivo. 2012;26(6):1057–1067.
   PubMed Web of Science ®Google Scholar
• Sethi G, Ahn KS, Pandey MK, et al. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB–regulated gene products and TAK1-mediated NF-κB activation. Blood. 2007;109(7):2727–2735.
   PubMed Web of Science ®Google Scholar
• Nazim UM, Yin H, Park S-Y. Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL-induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. Mol Med Rep. 2019;19:984–993.
   PubMed Web of Science ®Google Scholar
• Zhu H, Liu XW, Ding WJ, et al. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett. 2010;297(2):155–164.
   PubMed Web of Science ®Google Scholar
• Zhu H, Ding WJ, Wu R, et al. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest. 2010;28(1):23–32.
   PubMed Web of Science ®Google Scholar
• Wang GZ, Liu YQ, Cheng X, et al. Celastrol induces proteasomal degradation of FANCD 2 to sensitize lung cancer cells to DNA crosslinking agents. Cancer Sci. 2015;106(7):902–908.
   PubMed Web of Science ®Google Scholar
• Dai Y, DeSano JT, Meng Y, et al. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(4):1217–1225.
   PubMed Web of Science ®Google Scholar
• Lu Z, Jin Y, Qiu L, et al. Celastrol, a novel HSP90 inhibitor, depletes Bcr–Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. Cancer Lett. 2010;290(2):182–191.
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang W, He LJ, et al. Upregulating noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLOS ONE. 2012;7(12):e52333.
   PubMed Web of Science ®Google Scholar
• Chen M, Rose AE, Doudican N, et al. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res. 2009;7(12):1946–1953.
   PubMed Web of Science ®Google Scholar